Table 3.
Drug | Manufacturer | Target | Admin | Development status |
||
---|---|---|---|---|---|---|
Crohn’s disease | Ulcerative colitis | |||||
BLOCKADE PRO-INFLAMMATORY CYTOKINES | ||||||
TNF | Infliximab | MSD | TNF | IV | Approved in EU and USA | Approved in EU and USA |
Adalimumab | Abbvie | TNF | SC | Approved in EU and USA | Approved in EU and USA | |
Certolizumab pegol | UCB Pharma. | TNF | SC | Approved in USA | – | |
Golimumab | MSD | TNF | SC | – | Approved in EU and USA | |
CT-P13 | Celltrion, Hospira | TNF | IV | Approved in EU | Approved in EU | |
TNF-Kinoid | Neovacs | TNF | IV | Phase II (-) | – | |
HMPL-004 (Andrographis paniculata extract) | Hutchison Medipharma Limited | TNF and IL-1β | Oral | Ongoing Phase III | Ongoing Phase III | |
IL-12/IL-23 | Ustekinumab | Janssen | IL-12/IL-23 (p40 subunit) | IV/SC | Ongoing Phase III | – |
AMG139 | Amgen | IL-23/IL-23R interaction | IV | Ongoing Phase II | – | |
BI 655066 | Boehringer Ingelheim | IL-23 (p19 subunit) | SC | Ongoing Phase II | – | |
IL-6 | PF-04236921 | Pfizer | IL-6 | SC | Ongoing phase I/II | – |
IL-13 | Tralokinumab | AstraZeneca | IL-13 | SC | – | Phase II (-) |
Anrukinzumab | Pfizer | IL-13 receptor | IV | – | Phase II (-) | |
QAX576 | Novartis Pharmaceuticals | IL-13 | IV | Ongoing phase II | – | |
Bertilimumab | Immune Pharmaceuticals | Eotaxin-1 | IV | – | Ongoing phase II | |
IL-17 | Vidofluidimus | 4SC AG | IL-17 release | Oral | Phase II (+) | Phase II (+) |
IL-21 | ATR-107 (PF0530900) | Pfizer | IL-21 receptor | IV/SC | Ongoing phase I | – |
NNC0114-0006 | Novo Nordisk A/S | IL-21 | IV | Ongoing phase II | – | |
BLOCKADE OF THE DOWNSTREAM SIGNALLING PATHWAYS MEDIATED BY CYTOKINE | ||||||
JAK/STAT pathway | Tofacitinib | Pfizer | JAK1, 2 and 3 | Oral | Ongoing phase III | Ongoing phase III |
Peficitinib (JNJ-54781532) | Janssen | JAK1 | Oral | – | Ongoing phase II | |
GLPG0634 | Galapagos NV | JAK1 | Oral | Ongoing phase II | – | |
TGF-β | GED0301 | Giuliani | Smad7 antisense oligonucleotide | Oral | Phase I (+) | – |
IP-10 antagonists | BMS-936557 | Bristol-Myers Squibb | IP-10 | IV | Ongoing phase II | Phase II (±) |
Tyrosine kinase receptor | Masitinib (AB1010) | AB science | c-kit, PDGFR α/β; Lck, Lyn, FGFR-3; FAK | Ongoing phase II | – | |
ANTI-ADHESION MOLECULES | ||||||
Natalizumab | Tysabri, Biogen Idec | α4 | IV | Approved in USA | – | |
Vedolizumab | Millennium Pharma . | α4β7 | IV | Phase III (±) | Phase III (+) | |
Etrolizumab | Genentech | β7 | IV/SC | – | Phase II (+) | |
PF-00547659 | Pfizer | MadCAM-1 | IV/SC | Ongoing phase II | Ongoing phase II | |
AJM300 | Ajinomoto | α4 | Oral | – | Phase II (+) | |
Alicaforsen | ISIS Pharma. | ICAM-1 | Oral/intrarectal | Phase II (-) | Phase II (+) | |
Vatelizumab | Sanofi | α2β1 integrin | SC | – | Ongoing phase II | |
firategrast (SB-683699) (formerly T-0047) | GlaxoSmithKline | α4 | Oral | Ongoing phase II | – | |
GLPG0974 | Galapagos NV | FFA-2 | Oral | – | Ongoing phase II | |
TRK-170 | Toray Industries, Inc. | β7 | Oral | Ongoing phase II | – | |
ADMINISTRATION OF ANTI-INFLAMMATORY CYTOKINE | ||||||
IL-2 | Low dose IL-2 | ILTOO Pharma | IL-2 | SC | Ongoing phase II | Ongoing phase II |
BLOCKADE OF T-CELL STIMULATION AND INDUCTION OF APOPTOSIS | ||||||
SB012 | Sterna Biologicals GmbH & Co. KG | GATA-3 | Intrarectal | – | Ongoing phase I/II | |
VB-201 | VBL Therapeutics | TLR2 dependent innate cell activation | Oral | – | Ongoing phase II | |
GSK1399686 | GSK | Ribosomal 50S subunit | Oral | – | Ongoing phase II | |
Laquinimod | Teva Pharmaceutical Industries | ? | Oral | Phase II (+) | – | |
NNC 0142-0000-0002 | Novo Nordisk A/S | NKG2D | Ongoing phase II | – | ||
DIMS0150 | InDex Pharmaceuticals | TLR9 | Intrarectal | – | Ongoing phase III | |
OTHER MECHANISM | ||||||
Fingolimod | Mitsubishi Tanabe Pharma Corporation | sphingosine 1-phosphate 1 receptor | Oral | Ongoing phase I | – | |
RPC1063 | Receptos, Inc. | sphingosine 1-phosphate 1 receptor | Oral | – | Ongoing phase II | |
GSK1399686 | GSK | Ribosomal 50S subunit | Oral | – | Ongoing phase 2 |
FFA-2, free fatty acid receptor-2; ICAM-1, InterCellular Adhesion Molecule-1; infliximab; Ig, immunoglobulin; IL, interleukin; IP-10, interferon-γ-inducible protein-10; IV, intravenous; JAK, Janus kinase; Lck, lymphocyte-specific kinase; Lyn, Lck/Yes-related protein; MadCAM-1, mucosal address in cell adhesion molecule 1; NZB, natalizumab; NKG2D, natural killer group 2, member D; PDGFR α/β, platelet-derived growth factor receptor-α/β; SC, subcutaneous; TNF, tumor necrosis factor; TGF, transforming growth factor; TLR, Toll-like receptor.